

**U.S. Centers for Disease Control and Prevention**  
National Center for Immunization and Respiratory Diseases

# **Influenza Updates, Work Group Considerations, and Proposed Recommendations for the 2024-25 Influenza Season**

Lisa Grohskopf, Jill Ferdinands, and Lenee Blanton  
Influenza Division, CDC/NCIRD

June 27, 2024



# Acknowledgements

- Jill Ferdinands
- Lenee Blanton
  
- Lindsay Trujillo
- Joanna Taliano
- Andrew Leidner
- Rebecca Morgan
- Doug Campos-Outcalt



# Overview

- U.S. Influenza vaccine composition for the 2024-25 season
- Brief end-of-season influenza vaccine safety update
- Higher dose and adjuvanted influenza vaccines for solid organ transplant recipients: Evidence to Recommendations (EtR) Discussion
- Proposed recommendations for the 2024-25 season



# Influenza Updates



# U.S. Influenza Vaccine Composition for the 2024-25 Influenza Season

- All influenza vaccines marketed in the United States for the 2024-25 season will be trivalent
- There will be no influenza B/Yamagata component, following no confirmed detections of wild-type influenza B/Yamagata viruses since March 2020
- U.S. influenza vaccine composition for 2024-25 includes an update to the influenza A(H3N2) component:
  - An A/Victoria/4897/2022 (H1N1)pdm09-like virus for egg-based vaccines or an A/Wisconsin/67/2022 (H1N1)pdm09-like virus for cell and recombinant vaccines;
  - **An A/Thailand/8/2022 (H3N2)-like virus for egg-based vaccines or an A/Massachusetts/18/2022 (H3N2)-like virus for cell and recombinant vaccines;**
  - A B/Austria/1359417/2021 (B/Victoria lineage)-like virus



# **End-of-Season Update: 2023-2024 Influenza Vaccine Safety Monitoring**

**Immunization Safety Office**

**Centers for Disease Control and Prevention**

# Vaccine Safety Update: 2023-2024 Influenza Season

- **~158 million doses of influenza vaccine distributed in United States\***
- **Vaccine Adverse Event Reporting System (VAERS)** (co-managed by CDC and FDA)
  - No new safety concerns identified for influenza vaccines
- **Vaccine Safety Datalink (VSD)** (collaboration between CDC and 13 integrated healthcare organizations)
  - VSD monitors pre-specified outcomes using rapid cycle analysis (RCA)\*\*
  - ~4.8 million doses of influenza vaccine administered in VSD through 5/31/2024
  - No new safety concerns identified in influenza vaccine monitoring

\*As of March 9, 2024, [Weekly Flu Vaccination Dashboard](#) | [FluVaxView](#) | [Seasonal Influenza \(Flu\)](#) |


\*\* Outcomes monitored in VSD for influenza vaccines: acute disseminated encephalomyelitis (ADEM), anaphylaxis (case counts), Bell's palsy, encephalitis, Guillain-Barré syndrome, seizures, and transverse myelitis; Li et al. [Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013–2014 and 2014–2015 seasons \(wiley.com\)](#) *Pharmacoepidemiol Drug Saf.* 2016 Aug;25(8):928-34.

# Higher Dose and Adjuvanted Influenza Vaccines for Solid Organ Transplant Recipients: EtR Discussion

## Background



# Solid Organ Transplantation in the United States



U.S. Organ Transplants Performed, 2023	
All	46,632 (100)
By age group	
<18 years	1,916 (4)
18-64 years	33,610 (72)
≥65 years	11,104 (24)
Organ(s)	
Kidney	27,332 (59)
Liver	10,660 (23)
Heart	4,545 (10)
Lung	3,026 (6)
Kidney/pancreas	812 (2)
Pancreas	102 (0.2)
Heart/lung	54 (0.1)

# Recommendations for Influenza Vaccination of SOT Recipients

- Per ACIP recommendations, SOT recipients should receive an age-appropriate inactivated or recombinant influenza vaccine (i.e., an IIV or RIV)
  - Live attenuated influenza vaccine (LAIV) is not recommended for immunocompromised populations
- Immunosuppressive regimens might contribute to diminished response to vaccines
- High-dose (HD-IIV) and adjuvanted (aIIV) inactivated influenza vaccines have been studied in SOT recipients
- American Society for Transplantation (AST) states that high-dose or boosted dosing might be preferable post-transplant
- HD-IIV and aIIV are approved for ages  $\geq 65$  years, and might not be covered by insurance when administered to persons under age 65 years

# Policy Question

- Should high-dose inactivated, adjuvanted inactivated, and/or recombinant influenza vaccines be recommended as an option for influenza vaccination of solid organ transplant recipients who are younger than the approved age indication?
  - <65 years for high-dose and adjuvanted influenza vaccines
  - <18 years for recombinant influenza vaccine



# Public Health Importance

EtR Domain 1

# Public Health Importance—Scope of Population

- The number of transplants performed each year, and post-transplant survival have increased

Median recipient survival (years)		
Organ	1987-2012	1987-2021
Kidney	12.4	14.8
Liver	11.6	14.6
Heart	9.5	11.7
Lung	5.2	5.6
Pancreas	13.3	16.1

- Approximately 430,000 recipients alive in 2020
  - 0.1% of U.S. population

Recipients alive, n		
Organ	June 2015	June 2020
Kidney	200,000	255,738
Liver	74,945	98,842
Heart	29,172	37,419
Lung	12,100	17,500
Pancreas	14,161	19,458

\*Considering recipients of the most commonly transplanted organs, for whom systemic immunosuppression is generally required

OPTN/SRTR 2015 Annual Data Report

OPTN/SRTR 2020 Annual Data Report [2020 ADR \(hrsa.gov\)](https://www.hrsa.gov/2020-adr)

Organ Transplant and Procurement Network (OPTN). [National data - OPTN \(hrsa.gov\)](https://www.hrsa.gov/national-data)

Rana et al, JAMA Surgery 2015; 150(3):252-259

Ferreira et al, Digestive Diseases and Sciences 2023;68:3810-3817

# Public Health Importance—Disease Burden

- SOT recipients require lifelong immunosuppressive medications.
- Manifestations of influenza can be more severe
  - Lower respiratory tract disease, including pneumonia, occurs in 22-49% of SOT recipients
- In a 5-year cohort of SOT recipients with influenza (n=477):
  - 21% had lower respiratory tract disease on presentation
  - 69% were hospitalized
  - 11% admitted to an intensive care unit
  - 8% required mechanical ventilation
  - 3% died (all-causes) within 30 days



# WG Judgement: Public Health Importance

Is influenza among solid organ transplant recipients a problem of public health importance?

- No
- Probably no
- Probably yes
- Yes
- Varies
- Don't know



# Benefits and Harms

EtR Domain 2



# Population, Intervention, Comparator, and Outcomes

<b>Population</b>	Solid organ transplant recipients aged $\geq 6$ months
<b>Interventions</b>	High-dose (HD-IIV), MF59-djuvanted (aIIV), or recombinant (RIV) trivalent or quadrivalent influenza vaccines
<b>Comparator</b>	Single intramuscular dose of trivalent or quadrivalent unadjuvanted standard dose influenza vaccines
<b>Outcomes</b>	<p>Primary outcomes</p> <p>Benefits:</p> <ul style="list-style-type: none"><li>• Medically-attended influenza (Critical)</li><li>• Influenza-associated hospitalization (Critical)</li><li>• Laboratory-confirmed influenza—immunogenicity data acceptable (Important)</li></ul> <p>Harms:</p> <ul style="list-style-type: none"><li>• Transplant rejection or graft failure (Critical)</li><li>• Neuroinflammatory conditions , e.g. GBS, ADEM (Critical)</li><li>• Other immune-related adverse events, including new onset or exacerbation of an autoimmune condition (Critical)</li></ul>



# Study Characteristics (n=9)

- 9 papers describing 9 studies:
  - 8 randomized; 1 cohort
- Vaccines and comparisons:
  - HD-IIV<sub>3</sub> vs. SD-IIV<sub>3</sub> 2
  - Double-dose vs. single-dose SD-IIV<sub>3</sub> 2
  - aIIV<sub>3</sub> vs. SD-IIV<sub>3</sub> 3
  - aIIV<sub>3</sub> vs. HD-IIV<sub>3</sub> vs. SD-IIV<sub>4</sub> 1
  - aIIV<sub>3</sub> (most participants, no comparator) 1
  - No papers examining RIV
- Transplant populations:
  - Kidney 4
  - Heart 1
  - Mixed 4 (40-80% kidney)
- No papers reported on medically-attended influenza, neuroinflammatory conditions, or immune-mediated adverse events (all critical outcomes)
- Only one pediatric study (omitted from meta-analysis/GRADE)
- Cohort study excluded from GRADE given small size, lack of a comparison group, and availability of randomized studies
- 7 papers included in GRADE

# Summary—Benefits: aIV<sub>3</sub> vs SD-IIV

Outcome	N studies (n participants)	Pooled RR (95% CI)	GRADE Certainty	Importance
Influenza-associated hospitalization	1 (403)	2.90 (0.12, 70.71)	Low	Critical
Medically-attended influenza	0	-	-	Critical
Lab-confirmed influenza	1 (403)	0.97 (0.43, 2.18)	Moderate	Important
Seroconversion to H <sub>1</sub> N <sub>1</sub>	3 (558)	<b>1.37 (1.09, 1.72)</b>	Low	Important
Seroconversion to H <sub>3</sub> N <sub>2</sub>	3 (558)	<b>1.51 (1.25, 1.82)</b>	Low	Important
Seroconversion to B	3 (558)	<b>1.64 (1.28, 2.11)</b>	Low	Important
Seroprotection to H <sub>1</sub> N <sub>1</sub>	3 (558)	1.06 (0.98, 1.14)	Very low	Important
Seroprotection to H <sub>3</sub> N <sub>2</sub>	3 (558)	<b>1.20 (1.07, 1.33)</b>	Low	Important
Seroprotection to B	3 (558)	<b>1.17 (1.01, 1.34)</b>	Low	Important

# Summary—Benefits: HD-IIV<sub>3</sub> vs SD-IIV

Outcome	N studies (n participants)	Pooled RR (95% CI)	GRADE Certainty	Importance
Influenza-associated hospitalization	1 (393)	3.05 (0.12, 74.32)	Low	Critical
Medically-attended influenza	0	-	-	Critical
Lab-confirmed influenza	2 (565)	1.09 (0.52, 2.27)	Moderate	Important
Seroconversion to H <sub>1</sub> N <sub>1</sub>	2 (554)	<b>2.46 (1.86, 3.27)</b>	Moderate	Important
Seroconversion to H <sub>3</sub> N <sub>2</sub>	2 (554)	<b>1.67 (1.38, 2.02)</b>	Moderate	Important
Seroconversion to B	2 (554)	<b>1.90 (1.46, 2.46)</b>	Moderate	Important
Seroprotection to H <sub>1</sub> N <sub>1</sub>	2 (554)	1.03 (0.95, 1.11)	Low	Important
Seroprotection to H <sub>3</sub> N <sub>2</sub>	2 (554)	<b>1.13 (1.01, 1.26)</b>	Moderate	Important
Seroprotection to B	2 (554)	<b>1.22 (1.08, 1.38)</b>	Moderate	Important



# Summary—Harms

Outcome	Studies (N)	Pooled RR (95% CI)	GRADE Certainty	Importance
<b>aIIV<sub>3</sub> vs SD-IIV</b>				
Graft rejection	3 (517)	0.28 (0.06, 1.34)	Moderate	Critical
Neuroinflammatory events	0	-	-	Critical
Other autoimmune events	0	-	-	Critical
<b>HD-IIV<sub>3</sub> vs SD-IIV</b>				
Graft rejection	3 (579)	1.00 (0.32, 3.06)	Moderate	Critical
Neuroinflammatory events	0	-	-	Critical
Other autoimmune events	0	-	-	Critical



# Summary of Evidence: aIV<sub>3</sub> vs SD-IIV


Outcome	Importance	No. studies	Included in profile	Favored vaccine	Certainty
<b>Benefits</b>					
Medically-attended influenza	Critical	0	-	-	-
Influenza-associated hospitalization	Critical	1	Yes	Neither	Low
Laboratory-confirmed influenza	Important	1	Yes	Neither	Moderate
Immunogenicity (surrogate outcome)					
Seroconversion to A(H <sub>1</sub> N <sub>1</sub> )	Important	3	Yes	aIV <sub>3</sub>	Low
Seroconversion to A(H <sub>3</sub> N <sub>2</sub> )	Important	3	Yes	aIV <sub>3</sub>	Low
Seroconversion to B	Important	3	Yes	aIV <sub>3</sub>	Low
Seroprotection to A(H <sub>1</sub> N <sub>1</sub> )	Important	3	Yes	Neither	Very Low
Seroprotection to A(H <sub>3</sub> N <sub>2</sub> )	Important	3	Yes	aIV <sub>3</sub>	Low
Seroprotection to B	Important	3	Yes	aIV <sub>3</sub>	Low
<b>Harms</b>					
Transplant rejection/graft failure	Critical	3	Yes	Neither	Moderate
Neuroinflammatory conditions	Critical	0	-	-	-
Other immune-mediated adverse events	Critical	0	-	-	-

# Summary of Evidence: HD-IIV<sub>3</sub> vs SD-IIV

Outcome	Importance	No. studies	Included in profile	Favored vaccine	Certainty
<b>Benefits</b>					
Medically-attended influenza	Critical	0	-		-
Influenza-associated hospitalization	Critical	1	Yes	Neither	Low
Laboratory-confirmed influenza	Important	2	Yes	Neither	Moderate
Immunogenicity (surrogate outcome)					
Seroconversion to A(H <sub>1</sub> N <sub>1</sub> )	Important	3	Yes	HD-IIV <sub>3</sub>	Moderate
Seroconversion to A(H <sub>3</sub> N <sub>2</sub> )	Important	3	Yes	HD-IIV <sub>3</sub>	Moderate
Seroconversion to B	Important	3	Yes	HD-IIV <sub>3</sub>	Moderate
Seroprotection to A(H <sub>1</sub> N <sub>1</sub> )	Important	3	Yes	Neither	Low
Seroprotection to A(H <sub>3</sub> N <sub>2</sub> )	Important	3	Yes	HD-IIV <sub>3</sub>	Moderate
Seroprotection to B	Important	3	Yes	HD-IIV <sub>3</sub>	Moderate
<b>Harms</b>					
Transplant rejection/graft failure	Critical	3	Yes	Neither	Moderate
Neuroinflammatory conditions	Critical	0	-		-
Other immune-mediated adverse events	Critical	0	-		-

# Limitations

- Few studies; most are small (4 of 7 have <100 participants)
- No direct evidence of relative benefit or either HD-iiv3 or aIIV3 vs SD-IIV
  - Only indirect evidence (immunogenicity)
- Variability in timing of immunogenicity endpoints and how they are reported
- No information for critical outcomes of medically-attended influenza, neuroinflammatory conditions, or other immune-mediated events
  - Given study sizes, power probably not adequate
- No evaluations of RIV





# WG Judgement: Benefits and Harms

How substantial are the desirable anticipated effects?

- Minimal

- Small

- Moderate

- Large

- Varies

- Don't know



# WG Judgement: Benefits and Harms

How substantial are the undesirable anticipated effects?

▪ Minimal

▪ Small

▪ Moderate

▪ Large

▪ Varies

▪ Don't know



# WG Judgement: Benefits and Harms

Do desirable effects outweigh undesirable effects?

▪ Favors intervention

▪ Favors comparison

▪ Favors both

▪ Favors neither

▪ Varies

▪ Don't know



# Benefits and Harms: Certainty of Evidence

What is the overall certainty of the evidence for the critical outcomes?

## *Benefits of the intervention*

- No studies found
- Very low
- Low
- Moderate
- High

## *Harms of the intervention*

- No studies found
- Very low
- Low
- Moderate
- High

# Values and Preferences

EtR Domain 3

# Values and Preferences for Influenza Vaccine Types

- No direct evidence was identified reflecting values or preferences for specific influenza vaccine types among SOT recipients
- There might be a healthcare provider preference for HD-IIV, evidenced by the recommendations of the American Society for Transplantation and various transplant programs



# WG Judgement: Values

Does the target population feel that the desirable effects are large relative to undesirable effects?

- No
- Probably no
- Probably yes

▪ Yes

▪ Varies

▪ Don't know



# WG Judgement: Values

Is there important uncertainty about or variability in how much people value the main outcomes?

- Important uncertainty or variability
- Probably important uncertainty or variability
- Probably not important uncertainty or variability
- No important uncertainty or variability
- No known undesirable outcomes





# Acceptability

EtR Domain 4

# Acceptability Considerations

- Acceptability of a recommendation for high-dose vaccine is possibly evidenced by recommendations of the AST and some transplant programs for high-dose vaccine
- Acceptability might be limited among healthcare and public health systems and insurers by need for changes in standing orders, immunization information systems, and electronic medical record platforms



# WG Judgement: Acceptability

Is the intervention acceptable to key stakeholders?

- No
- Probably no

- Probably yes

- Yes

- Varies

- Don't know



# Resource Use

EtR Domain 5

# Is the Intervention a Reasonable and Efficient Allocation of Resources?

- No economic analysis was conducted:
  - Population ~430,000 as of 2020
  - Insufficient data concerning relative effectiveness of influenza vaccines in SOT populations
  - Insufficient data indicating extent to which use of these vaccines is already occurring among off-label age group SOT recipients
- HD-IIV<sub>3</sub> and aIIV<sub>3</sub> more costly (\$73-77) than unadjuvanted influenza vaccines (\$21-34)

# WG Judgement: Resource Use

Is the intervention a reasonable and efficient allocation of resources?

- No
- Probably no

▪ Probably yes

▪ Yes

▪ Varies

▪ Don't know



# Equity

EtR Domain 6

# Equity

- No literature was found concerning use of enhanced influenza vaccines among transplant recipients
- Among Medicare beneficiaries aged  $\geq 65$  years in a single-season (2015-16), Black, Asian, and Hispanic persons were 26% to 32% less likely to receive HD-IIV<sub>3</sub> than White persons
- A WG member noted other potential barriers for SOT recipients:
  - SOT recipients face barriers to receiving newer influenza vaccines as they are usually excluded from clinical trials, and there are few data for this population
  - Transplant programs with greater financial resources might be able to purchase vaccines for their patients, whereas those less well-resourced might not



# WG Judgement: Equity

What would be the impact on health equity?

- Reduced

- Probably reduced

- Probably no impact

- Probably increased

- Increased

- Varies

- Don't know



# Feasibility

EtR Domain 7

# Feasibility

## Factors favoring feasibility

- The recommendation might improve access, if more likely to be covered by insurance.
- If covered, insurance and reimbursement concerns should be minimal.
- Vaccination should be easily implementable in office and retail settings that serve adults.
- The vaccines are licensed and routinely stocked.

## Factors not favoring feasibility

- A recommendation stating that vaccines are acceptable options (as opposed to a preferential recommendation) might not compel insurers to cover them.
- Use of vaccine in a new age group might require changes in standing orders, Electronic Medical Record programming, and immunization information systems.

# WG Judgement: Balance of Consequences

Is the intervention feasible to implement?

- No
- Probably no

- Probably yes

- Yes

- Varies
- Don't know



# Balance of Consequences and Sufficiency of Information

# WG Judgement: Balance of Consequences

- Undesirable consequences *clearly outweigh* desirable consequences in most settings
- Undesirable consequences *probably outweigh* desirable consequences in most settings

▪ The balance between desirable and undesirable consequences *is closely balanced or uncertain*

▪ Desirable consequences *probably outweigh* undesirable consequences in most settings

▪ Desirable consequences *clearly outweigh* undesirable consequences in most settings

▪ There is insufficient evidence to determine the balance of consequences

# WG Judgement: Sufficiency of Information

Is there sufficient evidence to move forward with a recommendation

▪ Yes

▪ No



# Proposed Recommendations





# Proposed Recommendations for Influenza Vaccination, 2024-25 (For Vote)

- Routine annual influenza vaccination is recommended for all persons aged  $\geq 6$  months without contraindications.
  - *Same as previously*
- All persons should receive an age-appropriate influenza vaccine (i.e., one approved for their age), with the following exception: solid organ transplant recipients aged 18 through 64 years on immunosuppressive medication regimens may receive either HD-IIV<sub>3</sub> or aIIV<sub>3</sub> as an acceptable option (without a preference over other age-appropriate IIV<sub>3</sub>s or RIV<sub>3</sub>).

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

